Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PG101 in Dry Eye Syndrome
NCT02078661Phase 2Completed
- Sponsor
- Rhodes Pharmaceuticals
- Start
- Dec 2013
- Primary completion
- Jan 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of PG101 in dry eye syndrome (DED) (3 arms), sponsored by Rhodes Pharmaceuticals. Primary endpoint: At least one dry eye ocular symptom at 2 weeks. Started Dec 2013; status: completed.
02
Drugs
PG101
03
Conditions
dry eye syndrome (DED)
Beyond the preview
Go deeper on NCT02078661.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02078661.